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Abstract
Background:  Fanconi anemia (FA) is a complex recessive genetic disease characterized by
progressive bone marrow failure (BM) and a predisposition to cancer. We have previously shown
using the Fancc mouse model that the progressive BM failure results from a hematopoietic stem
cell defect suggesting that function of the FA genes may reside in primitive hematopoietic stem cells.
Methods:  Since genes involved in stem cell differentiation and/or maintenance are usually
regulated at the transcription level, we used a semiquantitative RT-PCR method to evaluate FA
gene transcript levels in purified hematopoietic stem cells.
Results: We show that most FA genes are highly expressed in primitive CD34-positive and
negative cells compared to lower levels in more differentiated cells. However, in CD34- stem cells
the Fancc gene was found to be expressed at low levels while Fancg was undetectable in this
population. Furthermore, Fancg expression is significantly decreased in Fancc -/- stem cells as
compared to wild-type cells while the cancer susceptibility genes Brca1 and Fancd1/Brac2 are
upregulated in Fancc-/- hematopoietic cells.
Conclusions: These results suggest that FA genes are regulated at the mRNA level, that increased
Fancc expression in LTS-CD34+ cells correlates with a role at the CD34+ differentiation stage and
that lack of Fancc affects the expression of other FA gene, more specifically Fancg and Fancd1/Brca2,
through an unknown mechanism.
Background
Fanconi anemia (FA) is a genetic autosomal recessive dis-
ease characterised by bone marrow (BM) failure associ-
ated with cancer susceptibility and congenital defects [1].
Somatic cell fusion studies of FA cells have revealed eight
complementation groups suggesting the existence of at
least eight genes implicated in the disease [2]. Six FA genes
have been cloned, FANCA,  FANCC,  FANCD2,  FANCE,
FANCF and FANCG and recently the Breast cancer suscep-
tibility gene, BRCA2, has been assigned to complementa-
tion group D1 and possibly to group B although this
requires further confirmation [3–10]. Knockout mouse
models from complementation group A (Fanca  -/-), C
(Fancc -/-) and G (Fancg -/-) have been generated in order
to study the molecular basis of this disease [11–14]. Bone
marrow (BM) failure similar to that observed in FA
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patients was shown in Fancc -/- mice after treatment with
a DNA damaging agent, mitomycin C, showing progres-
sive pancytopenia and reduced BM cellularity [15]. Also,
hematopoietic stem cells from Fancc -/- mice were shown
to have a reduced long-term reconstitution ability in
recipient mice concomitant with a reduced number of
primitive (Lin-) Thy1.2lowc-kit+Sca-1+CD34+ hematopoi-
etic cells [16,17]. These results suggest that FA genes may
be involved at specific stages of stem cell growth and/or
differentiation. Since genes involved in stem cell differen-
tiation are highly regulated at the RNA level [18–22], we
evaluated FA genes expression pattern in murine hemat-
opoietic cell populations more specifically in lineage-neg-
ative (Lin-) Thy1.2-Sca-1+CD34+ and Thy1.2-Sca-1+CD34-
stem cells. Our results show that in wild-type BM, FA
genes are highly expressed in the Lin-Thy1.2-Sca-1+CD34+
stem cell population and that Fanc  gene expression is
altered in Fancc -/- hematopoietic cells.
Methods
Hematopoietic cell purification
Bone marrow (BM) cells were obtained from 4 to 6 month
old Fancc -/- and Fancc +/+ mice (C57BL/6J, 11th genera-
tion of backcrosses) as previously described [17]. Bone
marrow were collected from femurs, tibias and humeri,
resuspended in PBS supplemented with 2% fetal bovine
serum (FBS, Life Technologies, Burlington, ON, Canada)
and depleted of red blood cells in ammonium chloride
solution (StemCell Technologies Inc., Vancouver, BC,
Canada) for 10 min at 4°C. Total BM cells were either
used for RT-PCR analysis or further divided into subpop-
ulations as follows. Total BM cells were depleted of line-
age (CD5, CD45R, CD11b, myeloid differentiation
antigen Gr-1, TER 119) and Thy1.2 positive cells using
StemSep negative cell selection procedure as described by
the manufacturer (StemCell Technologies Inc., Vancou-
ver, BC, Canada). The lineage and Thy1.2 depleted (Lin-)
cell population obtained was either used for gene expres-
sion analysis or further sorted into Sca-1+CD34+ (LTS-
CD34+) or Sca-1+CD34- (LTS-CD34-) populations as pre-
viously described [17]. Briefly, Lin-Thy1.2-  cells were
labeled with fluorochrome conjugated rat anti-mouse
antibodies directed against CD34 and Sca-1 antigens
(FITC-CD34 and PE-Sca-1, Ly-6A/E; PharMingen, Missis-
sauga, ON, Canada). Rat IgG2a monoclonal antibodies
conjugated to FITC or PE were used as isotype standards.
Cells were labeled 30 min at 4°C, washed and resus-
pended in PBS supplemented with 2% FBS. Cells were
sorted on an Epics Coulter cell sorter (BeckmanCoulter
Canada, Mississauga, ON, Canada). Cells were defined by
forward (FSC) and side (SSC) scatter and gated for Sca-1+
and CD34+ (LTS-CD34+) or CD34- (LTS-CD34-) popula-
tions (Figure 1A). Re-analysis of sorted Sca-1+CD34+ and
Sca-1+CD34- cells showed a purity of 85 to 95% in each
fraction (Figure 1B). Purity of each cell fraction was also
evaluated by RT-PCR as described below using specific
murine CD34 primers (Table 1). No CD34 mRNA expres-
sion was detected in sorted LTS-CD34- fraction (Figure
1C). Animal experiments were approved by the Animal
Care Committee of Laval University, QC, Canada.
RNA extraction and RT-PCR analysis
One to 5 × 106 of total hematopoietic or Lin-Thy1.2- cells
were used for total RNA purification and RT-PCR analysis.
Total RNA was extracted using TRIZOL reagent (Life tech-
nologies) as described by the manufacturer and
Figure 1
Sorting regions used for LTS-CD34+ and LTS-CD34- 
cell purification. (A) Lineage and Thy1.2 positive cells were 
removed from murine BM cell preparation as described in 
materials and methods. Lin-Thy1.2- cells were sorted on the 
basis of CD34 and Sca-1 expression using R1 and R2 sorting 
windows. (B) Reanalysis of sorted Lin-Thy1.2-Sca-1+CD34- 
and Lin-Thy1.2-Sca1+CD34+ cells. (C) Representative gel 
electrophoresis of RT-PCR products in sorted Lin-Thy1.2-
Sca1+CD34- and Lin-Thy1.2-Sca1+CD34+ cells from wild-type 
mice using either murine CD34 or Hprt primers.BMC Blood Disorders 2003, 3 http://www.biomedcentral.com/1471-2326/3/1
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resuspended in diethylpyrocarbonate (DEPC)-treated
water containing ribonuclease inhibitor Superase• in™ (1
U/µl, Ambion, Austin, TX, USA). For total BM and Lin-
Thy1.2- cells, RNA concentration was quantified by spec-
trophotometry at 260 nm and 400 ng of total RNA was
used for RT-PCR analysis. For LTS-CD34+ and LTS-CD34-
stem cell populations, the RNA extraction protocol was
modified to improve yield from small cell numbers rang-
ing from 5000 to 35000 cells. Briefly, total RNA was
extracted using TRIZOL reagent and precipitated with gly-
cogen as carrier. Each RNA preparation from LTS-CD34+
and LTS-CD34- stem cells was used directly in RT-PCR
reactions. The reverse transcription reaction was done
with oligo (dT) primers using the SuperScript™II protocol
as described by the manufacturer (Life technologies). For
PCR amplification, 10 to 20 % of cDNAs from each cell
preparation was directly added to a standard PCR ampli-
fication mixture. Sense and anti-sense primer sequences
and the corresponding cDNA PCR product sizes are
shown in Table 1. First, we determined optimal PCR con-
ditions for linear amplification of gene transcripts and to
avoid saturation conditions. Linear amplification of the
hypoxanthine guanine phosphoribosyl transferase gene
(Hprt) were obtained with cDNA obtained from 10 to 50
ng of total RNA or with RNA extracted from 6 000 to 60
000 hematopoietic cells (data not shown). Thirty cycles
for BM or Lin- cell RNA extract or 35 cycles for LTS-CD34+
or LTS-CD34- cell RNA extract was carried out and found
to be in the linear PCR reaction range. PCR products were
separated on 8% polyacrylamide gel and visualized by
ethidium bromide staining. Volumes of 5 or 10 ul of PCR
products were deposited on gels according to the expres-
sion level of each gene. Signal intensities were analyzed
using the BioRad Quantity one™ software. The relative
expression level for each target gene was quantified by cal-
culating the ratio of the target gene intensity signal to the
Hprt intensity signal obtained from the same cDNA prep-
aration and visualized on the same gel. Specificity of all
primers was further confirmed by direct nucleotide
sequencing analysis of PCR products. Each RNA extrac-
tion products were tested and found free of DNA contam-
ination using PCR amplification on samples without RT
reactions. Statistical analysis were performed using the
Student t-test.
Results
FA genes are highly expressed in murine wild-type primi-
tive hematopoietic cells
Several studies have surveyed changes in the expression
profiles of many genes associated with hematopoietic cell
growth and differentiation such as transcription factors,
cytokine receptors and ligands, cell cycle related genes and
integrins [18–22]. Since the hematopoietic defect in Fan-
coni anemia is thought to reside in the stem cell compart-
ment [17], we sought to determine the expression profile
of FA genes in murine hematopoietic stem and progenitor
cells. We evaluated the mRNA expression levels of FA
genes from complementation group A, C, D1/Brca2, D2,
E, F and G in sorted hematopoietic stem cell fractions
using a semiquantitative RT-PCR procedure. The relative
Table 1: Oligonucleotides primers used for PCR analysis
Genes Primer sequences Position on cDNA Size of PCR fragment Accession number
Fanca S 5'-tccttgtcagcgagatcatg 2955 457 XM125090
A 5'-cctgaagaagtggatggtaat 3412
Fancc S 5'-cttacggtgctccatgtcttg 1337 653 NM007985
A 5'-ctgagcagcatcaggagacgg 1990
Fancd1/Brca2 S 5'-agccccatgcagcctccacttg 9394 259 NM009765
A 5'-cggggacggtaagggcagcc 9653
Fancd2 S 5'-gccgggctttgagatgatc 913 418 AK019136
A 5'-ccgtgcagggaccagaaca 1331
Fance S 5'-ggccctcgtctccttctgtg 1103 246 AK013325
A 5'-gctctgctgctctgtgatctg 1349
Fancf S 5'-cacgaggtccctacacagatggaggacatg ND 228 *H.Joenje
A 5'-agcctgggaactgagaatctactctagcac
Fancg S 5'-tccccacccacctcctctctag 1176 317 AY049715
A 5'-caggcagggtccgaaagagcag 1493
Brca1 S 5'-cagcgggcgaccatgaagtataa                          4260 304 XM126697
A 5'-ggccttcccatccctgactcgt 4564
Hprt S 5'-agtcccagcgtcgtgattag 100 269 NM013556
A 5'-aggaatggatctatcactat 369
CD34 S 5'-atgcaggtccacagggacacg 51 220 BC006607
A 5'-ctgtcctgatagatcaagtag 271
S, sense; A, anti-sense; ND, unkown *Primer sequences provided by Dr. H Joenje, Free University AmsterdamBMC Blood Disorders 2003, 3 http://www.biomedcentral.com/1471-2326/3/1
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expression of each FA gene was based on the housekeep-
ing gene Hprt transcription level (equivalent to 1) in each
sample tested allowing the comparison of Fanc  gene
expression levels between murine BM, lineage and
Thy1.2-depleted, LTS-CD34+ and LTS-CD34- hematopoi-
etic cells. We found that Fanca, Fancc, Fancd2 and Fancg
were highly expressed in LTS-CD34+ cells (Fanc/Hprt ratios
ranging from 0.45 to 0.75) whereas Fancd1/Brca2, Fance,
Fancf  and the FA-associated cancer susceptibility gene
Brca1 were expressed at low levels in these cells with ratios
ranging from 0.09 to 0.30 (Figure 2 and 4). Expression of
all Fanc genes tested was dramatically low in both BM and
Lin-Thy1.2- cells with relative expression ranging from
0.029 to 0.36. Both Fance and Fancf were expressed at low
levels in all BM cell populations tested with relative
expression of 0.07 to 0.27 and 0.14 to 0.30 respectively.
Adult murine long-term repopulating stem cells are
thought to reside in the CD34- cell compartment while
CD34+ cells have short-term reconstitution potential [23–
25]. We measured Fanc gene mRNA expression in the LTS-
CD34- cell fraction. Our results show that Fanca is highly
expressed in LTS-CD34- cells (ratio of 0.875 ± 0.045)
whereas other Fanc genes showed low mRNA expression
levels (ratio ranging from 0.085 to 0.33). In addition, we
were unable to detect Fancg expression in LTS-CD34- stem
cells (4 independent reactions). Our results suggest that
most Fanc genes, and more dramatically Fancc and Fancg
are upregulated in murine LTS-CD34+ cells correlating
with a specific role at this hematopoietic cell differentia-
tion stage.
Fanc genes are disregulated in Fancc-/- hematopoietic cells
We investigated the expression levels of Fanc genes in
Fancc-/- hematopoietic cells in order to verify if absence of
one FA gene, notably the murine Fancc, affects the expres-
sion profile of other Fanc genes. Our results show that
Fanca, and Fancd2 are significantly upregulated in Fancc -
/- total BM cells as compared to Fancc+/+ cells while
Fance, Fancf and Fancg expression levels are either down
regulated or unchanged (Figure 3). Similarly, Fanca
showed a 7 fold significant increase in mRNA expression
in Fancc-/- progenitors (Lin-Thy1.2-) compared to Fancc+/
+ cells (Table 2). Surprisignly, Fancc-/- progenitor cells
showed lower Fancd2 mRNA levels with an expression
ratio of 0.18 compared to Fancc+/+ cells while Fance,
Fancf and Fancg expression levels were similar between
Fancc -/- and Fancc+/+ Lin-Thy1.2- cells.
We also evaluated Fanc mRNA expression in both CD34+
and CD34- stem cells. We show that Fancg expression is
significantly decreased in Fancc-/- LTS-CD34+ cells as com-
pared to Fancc+/+ cells (ratio of 0.06). Again, Fancg
expression could not be detected in Fancc-/- LTS-CD34-
cells as in Fancc+/+ cells. Other Fanc genes, Fanca, Fancd2,
Fance or Fancf, did not show any significant changes in
mRNA expression in Fancc-/- LTS-CD34+ and Fancc-/- LTS-
CD34- cells as compared to Fancc+/+ cells. These results
suggest that absence of Fancc influences mRNA expression
levels of other Fanc genes in progenitors and total BM
cells.
The breast cancer susceptibility genes, Brca1 and Brca2/
Fancd1 are upregulated in Fancc -/- hematopoietic cells
We evaluated mRNA expression levels of the newly iden-
tified FA gene Brca2/Fancd1, and the FA-associated gene,
Brca1, in Fancc+/+ and Fancc-/- hematopoietic cells. We
found that both Brca2/Fancd1  and  Brca1  genes were
expressed at low levels in all Fancc+/+ hematopoietic cell
populations tested (ratios ranging from 0.29 to 0.36 and
0.09 to 0.24, respectively; Figure 4). We also evaluated
mRNA levels in Fancc-/- hematopoeitic cells and found
that both Brca2/Fancd1  and  Brca1  are upregulated in
Fancc-/- total BM, progenitors and CD34+ cells. Of all the
FA genes tested, Fancd1/Brca2 and the FA associated gene
Brca1 seemed to be the most affected from absence of
Fancc with 5 to 7 fold increase in gene expression levels in
Fancc-/- differentiated BM cells and progenitors (Lin-
Thy1.2-), respectively (Table 2).
Table 2: FA gene expression ratios in Fancc -/- hematopoietic cell population as compared to Fancc+/+ cells
BM Lin-Thy1.2- LTS-CD34+ LTS-CD34-
Fanca 5.1 ↑ 7.0 ↑ 0.45 1.3
Fancd1/Brca2 3.3↑ 2.6↑ 2.9 0.58
Fancd2 4.3 ↑ 0.18 ↓ 0.76 1.5
Fance 0.75 ↓ 0.95 1.5 0.37
Fancf 1.1 1.1 0.46 0.79
Fancg 1.8 1.3 0.06 ↓ -
Brca1 7.0↑ 2.5↑ 1.7 1.7
↑ Significant increased expression levels in Fancc -/- cells; ↓ Significant decreased expression levels in Fancc -/- cells -: Gene expression not detected 
neither in Fancc +/+ nor Fancc -/- cellsBMC Blood Disorders 2003, 3 http://www.biomedcentral.com/1471-2326/3/1
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It is difficult to know if the observed increase in Brca gene
expression in Fancc-/- hematopoietic cells is also reflected
at the protein level. Since there are no commercially avail-
able antibodies directed against murine Brca proteins, we
used anti-human BRCA1 and BRCA2 antibodies in West-
ern blot and immunoprecipitation techniques and could
not detect murine Brca1 and Brca2 proteins (data not
shown). Thus, we could not evaluate protein expression
levels in Fancc-/- BM cells to determine if the observed
mRNA expression profiles correlated with protein expres-
sion levels.
Nevertheless, these results suggest that absence of Fancc
affects the regulation of other Fanc gene expression more
dramatically, Brca2/Fancd1 and Brca1, through an
unknown mechanism.
Discussion
Gene expression profiling and transcription regulation of
different genes can be surveyed using several techniques
such as Northern blots, differential display or microarray
technology. Some may provide information on numerous
genes simultaneously such as microarrays, but these tend
to generate large and complex data. We chose a simple
direct semiquantitative RT-PCR procedure to characterize
specific gene expression levels in sorted hematopoietic
stem and progenitor cell fractions. Since primitive
hematopoietic stem cells are only obtainable in very lim-
ited amounts, PCR based methods are more sensitive and
Figure 2
Fanc gene expression profiles in murine hematopoietic cells. (A) Representative gel electrophoresis of 10 ul (* repre-
sents 5 ul) of RT-PCR products from wild-type BM (BM), lineage and Thy1.2-depleated (Lin-) and sorted LTS-CD34+ (CD34+) 
and LTS-CD34- (CD34-) cells using specific Fanc and Hprt primers. (B) Mean relative expression of Fanc genes in wild-type 
hematopoietic cell populations from 2 to 10 separate determinations with the exception of Fancf in CD34- cells where values 
represent one determination. Fancg expression in CD34- cells was undetectable (n= 4).BMC Blood Disorders 2003, 3 http://www.biomedcentral.com/1471-2326/3/1
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allow the detection of low abundance transcripts in small
cell populations as compared to Northern blot analysis. In
addition, we used single-round PCR amplifications fol-
lowed by direct detection on polyacrylamid gels to keep
relative abundance relationship between transcripts and
to reduce variability between samples. The reverse tran-
scription was performed using oligo (dT) primers and tar-
get gene expression ratios were based on the
housekeeping gene, Hprt, transcription level (equivalent
to 1.0) in the same sample, thus, allowing the comparison
between different genes, between cell populations and
between wild-type and Fancc -/- cells.
In the current study, we tested the hypothesis that Fanc
genes display a pattern of expression reminiscent of a role
in hematopoietic stem cell differentiation and/or mainte-
nance. Based on phenotypic analysis of Fancc -/- mouse
bone marrow, targeted deletion of Fancc  alleles was
shown to affect the number of primitive CD34+  cells
suggestive of a role at the CD34+ stem cell differentiation
stage [17]. We found that expression of most FA genes,
notably,  Fanca,  Fancc,  Fancd2  and  Fancg, are highly
expressed in CD34+ stem cells as compared to more differ-
entiated cell populations whereas Fance  and  Fancf  are
expressed at similar levels in all hematopoietic cell popu-
Figure 3
Comparative analysis of Fanc gene expression in hematopoietic cells from Fancc-/- mice. (A) Representative gel 
electrophoresis of 10 ul (* represents 5 ul) of RT-PCR products from Fancc -/- BM cells, BM; lineage and Thy1.2-depleated, Lin-
; sorted LTS-CD34+, CD34+; and LTS-CD34-, CD34- cells using specific Fanc and Hprt primers. (B) Quantitative comparison of 
the expression levels of Fanc genes in hematopoietic cell populations from Fancc+/+ and Fancc-/- mice. Bars represent the mean 
value from 2 to 10 separate determinations with the exception of Fance and Fancf in CD34- cells where values represent one 
determination. Fancg expression in CD34- cells was undetectable in both Fancc+/+ (n= 4) and Fancc-/- cells (n= 4). Fancc +/+ 
expression ratios are identical to those in Figure 2. Significant differences between Fancc -/- and Fancc +/+ cells where * p < 
0.05, ** p < 0.005 and † p < 0.001.BMC Blood Disorders 2003, 3 http://www.biomedcentral.com/1471-2326/3/1
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lations. We showed that Fanca was highly expressed in
both long-term CD34- and short-term CD34+ stem cells
whereas Fancc and Fancg appear to be downregulated in
LTS-CD34- stem cells and upregulated in CD34+ cells con-
sistent with a role of Fancc at the CD34- to CD34+ differ-
entiation stage[17]. The fact that Fancg is undetectable in
CD34- stem cells and highly expressed in CD34+ cells sug-
gest that this gene may also function at the CD34+ stage.
Taken together, these results suggest that Fanc genes are
differently regulated in hematopoietic stem cells and sug-
gest that each FA proteins may act separately from the FA
complex during hematopoiesis similarly to what has been
suggested for MMC sensitivity and cytokine signaling [26–
29].
Our results showing increased Fanca and Fancc expression
in primitive hematopoietic stem cells and reduced levels
in differentiated BM cells are consistent with previous
studies showing Fanca and Fancc expression in cells of
mesenchymal origin that give rise to hematopoietic
tissues during mouse development [30]. In addition, stud-
ies showing Fancc expression in areas undergoing osteo-
genesis, in regions containing dividing and/or
differentiating cells, in progenitor/precursor cell popula-
Figure 4
Comparative analysis of Brca1 and Brca2/Fancd1 gene expression in hematopoietic cells from Fancc-/- mice. (A) 
Representative gel electrophoresis of 10 ul and 5 ul of RT-PCR products using specific Brca1 or Brca2/Fancd1 and Hprt primers, 
respectively, from Fancc -/- BM cells, BM; lineage and Thy1.2-depleated, Lin-; sorted LTS-CD34+, CD34+; and LTS-CD34-, 
CD34- cells. (B) Quantitative comparison of the expression levels of Brca1 and Brca2/Fancd1 genes in hematopoietic cell popu-
lations from Fancc+/+ and Fancc-/- mice. Bars represent the mean value from 4 to 10 separate determinations. Absence of SEM 
bars represents values to low to appear. Significant differences between Fancc -/- and Fancc +/+ cells where *p < 0.05 and ** p 
< 0.005.BMC Blood Disorders 2003, 3 http://www.biomedcentral.com/1471-2326/3/1
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tions and in primordial germ cell development are also
consistent with our results showing elevated Fancc expres-
sion in primitive hematopoietic cells [20,32–34].
Mouse models for Fanca, Fancc and Fancg have been gen-
erated [11–14] and were shown to display similar pheno-
types, these include hypersensitivity to DNA crosslinking
agents, increased spontaneous and induced chromosomal
breakage and germ cell loss leading to reduced fertility.
Studies using the Fancc -/- mice have shown that lack of
Fancc resulted in a reduced number of CD34+ stem cells
[17]. Since the murine CD34 marker has been associated
not only with the differentiation state or short-term
repopulating cells, but also with activation and/or cycling
state [24,35], the reduced number of CD34+ cells in Fancc-
/- mice and the fact that Fancc-/- stem/progenitor cells
(Lin-c-Kit+Sca-1+) were shown to be less quiescent [36]
may also reflect an altered activation state. Murine Brca1
and Brca2 mRNA expression was shown to be up-regu-
lated in rapidly proliferating cells indicative of a role in
proliferation and differentiation control [37]. Also,
murine Fancg mRNA was shown to be expressed in highly
proliferative and embryonic tissues [31]. Since Fancc-/-
progenitor/stem cells were shown to be less quiescent
[36], our results showing increased Brca1  and  Brca2/
Fancd1 mRNA expression levels in Fancc-/- BM cells would
be consistent with an altered proliferation state. However,
this is not the case with Fancg expression pattern, where
mRNA levels were found to be dramatically reduced in
Fancc -/- LTS-CD34+ cells. Thus, the increased expression
levels of Brca1  and  Brca2/Fancd1  in  Fancc-/- cells and
reduced Fancg expression in CD34+ cells may not be a
consequence of an increase in proliferation but may
reflect disregulated gene expression due to absence of
Fancc. The role that Fancc might have on other FA gene
expression has yet to be determined.
Conclusions
Together our results show that FA genes are regulated at
the mRNA level that increased Fancc expression in LTS-
CD34+ cells correlates with a role at the CD34+ differenti-
ation stage and that lack of Fancc downregulates Fancg
expression in CD34+ stem cells but increases Brca1 and
Brca2/Fancd1 expression in all BM cell populations. Dif-
ferential expression of FA genes in hematopoietic cell
population suggest that FA genes may have distinct func-
tion at different stem cell stages but that Fancc and Fancg
may function specifically at the CD34+  differentiation
stage.
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